Author:
Cohen Stanley B.,Alten Rieke,Kameda Hideto,Hala Tomas,Radominski Sebastiao C.,Rehman Muhammad I.,Palaparthy Ramesh,Schumacher Karl,Schmitt Susanne,Hua Steven Y.,Ianos Claudia,Sewell K. Lea
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. European Medicines Agency (EMA). Remicade (infliximab) summary of product characteristics. London: EMA; 2017.
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000240/WC500050888.pdf
. Accessed 14 Aug 2017.
2. Janssen Biotech Inc. Remicade (infliximab) US prescribing information. Horsham, PA: Janssen Biotech, Inc.; 2017.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761072s000lbl.pdf
. Accessed 14 Aug 2017.
3. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med. 2000;343:1594–602.
4. St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50:3432–43.
5. Kalo Z, Voko Z, Ostor A, Clifton-Brown E, Vasilescu R, Battersby A, et al. Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region. J Mark Access Health Policy. 2017;5:1345580.
Cited by
52 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献